Physician profile
Patrick G Young
NPI 1508082652
$18,566.91
in general payments reported to CMS, 2019-2025
13 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,600 · 2020: $86.33 · 2021: $3,995 · 2022: $2,721 · 2023: $1,403 · 2024: $440 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,050 · Food and Beverage: $1,015 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,050.00 |
| Food and Beverage | $1,014.79 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $9,174.93 | 2019 | |
| Abbvie INC. | $7,989.70 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $444.47 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $282.49 | 2020-2024 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $207.38 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $120.51 | 2024-2025 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.53 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $78.08 | 2024-2025 | Austedo Xr, Austedo Xr |
| Corium, LLC | $47.34 | 2024-2025 | Azstarys |
| Axsome Therapeutics, INC. | $45.47 | 2025 | Auvelity |
| Indivior INC. | $44.67 | 2024 | Perseris |
| Ironshore Pharmaceuticals INC. | $18.96 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.38 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.